Literature DB >> 10525756

Selective effects of nicotine on attentional processes.

G Mancuso1, D M Warburton, M Mélen, N Sherwood, E Tirelli.   

Abstract

RATIONALE: It is now well established from electrophysiological and behavioural evidence that nicotine has effects on information processing. The results are usually explained either by a primary effect of nicotine or by a reversal effect of a nicotine-induced, abstinence deficit. In addition, there is dispute about the cognitive processes underlying the changes in performance.
METHODS: This study has approached the first question by using the nicotine patch, in order to administer nicotine chronically. In addition, we examined the effects of nicotine on attention with a selection of tests which assessed the intensity and selectivity features of attention, using the Random Letter Generation test, the Flexibility of Attention test and the Stroop test.
RESULTS: Nicotine enhanced the speed of number generation and the speed of processing in both the control and interference conditions of the Stroop test. There were no effects on attentional switching of the Flexibility of Attention test.
CONCLUSION: The results are consistent with the hypothesis that nicotine mainly improves the intensity feature of attention, rather than the selectivity feature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525756     DOI: 10.1007/s002130051107

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  Effects of nicotine chewing gum on a real-life motor task: a kinematic analysis of handwriting movements in smokers and non-smokers.

Authors:  Oliver Tucha; Klaus W Lange
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

2.  The early time course of smoking withdrawal effects.

Authors:  Peter S Hendricks; Joseph W Ditre; David J Drobes; Thomas H Brandon
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

3.  Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers.

Authors:  Mehmet Sofuoglu; James Poling; Maria Mouratidis; Thomas Kosten
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

Review 4.  Neuromodulation by glutamate and acetylcholine can change circuit dynamics by regulating the relative influence of afferent input and excitatory feedback.

Authors:  Lisa M Giocomo; Michael E Hasselmo
Journal:  Mol Neurobiol       Date:  2007-07-20       Impact factor: 5.590

5.  Effects of cigarette smoking and abstinence on Stroop task performance.

Authors:  Catherine P Domier; John R Monterosso; Arthur L Brody; Sara L Simon; Adrianna Mendrek; Richard Olmstead; Murray E Jarvik; Mark S Cohen; Edythe D London
Journal:  Psychopharmacology (Berl)       Date:  2007-07-19       Impact factor: 4.530

6.  Effects of nicotine on response inhibition and interference control.

Authors:  Ulrich Ettinger; Eliana Faiola; Anna-Maria Kasparbauer; Nadine Petrovsky; Raymond C K Chan; Roman Liepelt; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

7.  Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers.

Authors:  Mehmet Sofuoglu; Maria Mouratidis; Marc Mooney
Journal:  Psychoneuroendocrinology       Date:  2010-08-02       Impact factor: 4.905

8.  Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.

Authors:  Alexandra S Potter; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 9.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 10.  [Why do schizophrenic patients smoke?].

Authors:  K Cattapan-Ludewig; S Ludewig; E Jaquenoud Sirot; M Etzensberger; F Hasler
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.